BioStock: Spago Nanomedical's CDO on study submission

Spago Nanomedical recently submitted the application to start the phase I/IIa study with Tumorad in Australia. Spago's Chief Development Officer Paul Hargreaves visited BioStock's studio to talk about the new radionuclide therapy and the upcoming study.

Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2023/05/spago-nanomedicals-cdo-on-study-submission/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/